1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Plasma tumour necrosis factor-alpha-related proteins in prognosis of heart failure with pulmonary hypertension
(
- Contribution to journal › Article
- 2022
-
Mark
Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery
(
- Contribution to journal › Article
-
Mark
Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
(
- Contribution to journal › Article
- 2021
-
Mark
Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Underfilling decreases left ventricular function in pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2020
-
Mark
Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics
(
- Contribution to journal › Article
-
Mark
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy : a registry-based study
(
- Contribution to journal › Article